High Purity ATIPA Iohexol Intermediate Synthesis Route
Achieving Consistent Yields and Pharmaceutical Grade Purity
Procurement executives and process chemists face significant challenges when sourcing critical contrast agent precursors. Inconsistent industrial purity levels often lead to costly downstream purification failures and batch rejections. At NINGBO INNO PHARMCHEM CO.,LTD., we understand that variability in the iodination step directly impacts the safety profile of the final X-ray contrast intermediate. Our focus is on delivering stable supply chains with verified specifications that meet stringent pharmacopeial standards.
Troubleshooting common impurities and yield issues
Mitigating Mono and Di-Iodo Impurities
Incomplete iodination during the synthesis of 2,4,6-Triiodo-5-aminoisophthalic acid frequently results in mono and di-iodo byproducts. These structural analogs are difficult to separate and can compromise the efficacy of the final Iohexol intermediate. Advanced process control and optimized halogenating agents are essential to minimize these deviations and ensure high conversion rates.
Eliminating Residual Solvents and Heavy Metals
Residual solvents such as isopropanol or methanol, along with heavy metal catalysts, pose significant regulatory risks. Strict purification protocols, including silica gel treatment and controlled crystallization, are required to reduce these contaminants to ppm levels. This ensures the material is safe for use in the production of Ioversol synthesis and other non-ionic monomer contrast agents.
Detailed chemical synthesis route and reaction mechanism
The manufacturing process begins with the nitration of isophthalic acid, followed by reduction to 5-amino isophthalic acid. The critical step involves the halogenation using agents like HICl2 to achieve tri-iodination. This produces 5-Amino-2,4,6-triiodoisophthalic acid with high structural integrity. Subsequent steps may involve conversion to acid chlorides and amidation. As a global manufacturer, we optimize each reaction phase to maximize yield while maintaining the strict purity profiles required for pharmaceutical grade applications.
Strict Quality Assurance (QA) workflow and COA verification process
Quality assurance is embedded at every stage of production. Each batch undergoes rigorous HPLC analysis to confirm purity levels exceeding 98%. Our COA verification process includes testing for related substances, residual solvents, and heavy metals. NINGBO INNO PHARMCHEM CO.,LTD. provides full traceability and documentation to support regulatory filings and ensure batch-to-batch consistency for your production lines.
To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.